DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Daclizumab - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Immunomodulatory Agents
  • Immunosupressants

Dosage Forms

  • Solution (IV)

Brands / Synonyms

Anti-IL-2; Humanized antiCD25; Ig gamma-1 chain C region; Zenapax; Zenapax (Hoffmann-La Roche Inc)

Description

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.

Indications

For prevention of renal transplant rejection

Pharmacology

Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

Mechanism of Action

Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Absorption

Not Available

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes.

Contraindications

Not Available

Drug Interactions

Not Available

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017